Stocktoria
CITIUS ONCOLOGY, INC. CTOR
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2022-10-14
CITIUS ONCOLOGY, INC. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| R&D expense | $6.4M | $4.9M | — | $4.2M | — |
| Operating income | -$23.5M | -$20.6M | -$1.0M | — | -$138,115 |
| Interest expense | $218,032 | — | — | — | — |
| Income tax | $1.1M | $576,000 | — | $576,000 | — |
| Net income | -$24.8M | -$21.1M | $2.4M | -$12.7M | $380,811 |
| EPS (diluted) | $-0.34 | $-0.31 | $0.27 | $-0.19 | $0.12 |
| Operating cash flow | -$5.5M | $126,353 | -$601,304 | — | -$47,968 |
| Cash & equivalents | $3.9M | $112 | — | — | — |
| Inventory | $22.3M | $8.3M | — | — | — |
| Total assets | $100.9M | $84.4M | $72.6M | $47.7M | $68.2M |
| Total liabilities | $56.1M | $38.2M | — | $22.2M | — |
| Shareholders' equity | $44.9M | $46.1M | $22.7M | $25.5M | $345,508 |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Net income growth | — | -974.2% | — | -3434.3% | — |
| EPS growth | — | -214.8% | — | -258.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.